Could Diabetes Drugs Help Protect Against Prostate Cancer?
 |
This figure shows cumulative incidence curves comparing prostate cancer risk between men taking GLP-1 receptor agonists (GLP-1RA, shown in blue) versus those taking basal insulin (shown in black) over a 12-year follow-up period. It's from the Danish nationwide cohort study. Key Elements:Panel a: Intention-to-Treat Analysis
Panel b: Per-Protocol Analysis
What This Means:The per-protocol analysis (panel b) shows the protective effect more clearly because it measures the actual effect while patients are taking the medication. The separation of the curves demonstrates that men taking GLP-1 receptor agonists had consistently lower prostate cancer incidence over time compared to those taking insulin. The fact that the curves diverge (separate) rather than run parallel suggests a genuine protective effect that increases with continued use, rather than just a delay in diagnosis. This visual data supports the 20% risk reduction (HR 0.80) reported in the study's per-protocol analysis. |
GLP-1 Agonists and Cancer: Parsing Safety Signals in the Weight-Loss Drug Boom
New Research Explores Promising Link Between GLP-1 Agonists and Reduced Cancer Risk
IPCSG Newsletter – October 2025
If you've been following health news lately, you've probably heard about GLP-1 agonist medications like Ozempic, Wegovy, and Mounjaro. These drugs have gained widespread attention for helping people manage diabetes and lose weight. But emerging research suggests they may offer an unexpected benefit: protection against prostate cancer.
What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a natural hormone in your body that helps regulate blood sugar and appetite. Originally developed for type 2 diabetes, these drugs have proven remarkably effective for weight management as well.
Common GLP-1 agonists include:
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss)
- Liraglutide (Victoza for diabetes, Saxenda for weight loss)
- Exenatide (Byetta, Bydureon)
- Dulaglutide (Trulicity)
- Tirzepatide (Mounjaro) – a dual GIP/GLP-1 receptor agonist
The Prostate Cancer Connection: What Research Shows
Several recent studies have discovered an intriguing relationship between these medications and prostate cancer risk. The evidence is encouraging:
Large-Scale Population Studies
A major Danish nationwide study published in the journal Diabetologia tracked over 35,000 men for approximately five years. Researchers found that men taking GLP-1 receptor agonists had a 20% lower risk of developing prostate cancer compared to those taking insulin. This protective effect was especially strong in older men and those with cardiovascular disease.
Even more impressive, a comprehensive meta-analysis published in 2024 examined five separate studies and found that GLP-1 receptor agonist use was associated with a 28% reduction in prostate cancer risk compared to placebo or other diabetes medications.
The LEADER Trial Findings
Post-analysis of the LEADER clinical trial, which included over 9,000 patients, revealed that men taking liraglutide had approximately half the risk of developing prostate cancer compared to those receiving placebo.
Recent Real-World Data
Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting examined nearly 2 million prostate cancer patients in the United States. The study found that use of GLP-1 agonists among men with prostate cancer has increased dramatically—from just 1,245 patients in 2015 to 69,808 in 2024. Importantly, doctors are increasingly prescribing these medications to prostate cancer patients even when they don't have traditional indications like diabetes or obesity, suggesting growing confidence in potential benefits.
How Might These Drugs Protect Against Prostate Cancer?
Scientists have identified several mechanisms that may explain the protective effect:
Direct Effects on Cancer Cells
Research has confirmed that GLP-1 receptors are present in prostate cancer tissue. Laboratory studies show that GLP-1 agonists can slow the growth of prostate cancer cells by interfering with signaling pathways that cancer cells use to multiply and survive. Specifically, these drugs appear to block the ERK-MAPK pathway, which is important for cancer cell proliferation.
Reducing Inflammation
Chronic inflammation plays a role in cancer development, and obesity is associated with increased inflammation throughout the body. GLP-1 agonists have been shown to reduce systemic inflammation, which may help create an environment less favorable for cancer growth.
Metabolic Benefits
These medications improve insulin sensitivity and reduce insulin resistance—both factors that have been linked to more aggressive prostate cancer. By addressing metabolic syndrome (a cluster of conditions including high blood pressure, high blood sugar, and abnormal cholesterol levels), GLP-1 agonists may reduce cancer risk indirectly.
Improving Immune Function
A 2023 study published in the journal Obesity found that semaglutide can restore the function of natural killer cells—specialized immune cells that help the body fight cancer. In people with obesity, these cells often become less effective, but GLP-1 agonists appear to reverse this impairment.
Increasing Use Among Prostate Cancer Patients
As awareness of these potential benefits grows, more men with prostate cancer are being prescribed GLP-1 agonists. The 2025 ASCO data shows particularly interesting trends:
- About 6% of prostate cancer patients now use these medications—matching the rate in the general population
- In 2024, 81% of prostate cancer patients on GLP-1 agonists had type 2 diabetes (down from 87% in 2015)
- An increasing number of patients are receiving these drugs without traditional diabetes or obesity indications, suggesting doctors may be prescribing them for potential cancer-related benefits
- Patients with lower social vulnerability and those who are obese are more likely to receive these medications
What This Means for Men with Prostate Cancer
The relationship between androgen deprivation therapy (ADT)—a common prostate cancer treatment—and metabolic health is particularly relevant. ADT often leads to weight gain and increased cardiovascular risks, creating a perfect storm for metabolic syndrome. This makes GLP-1 agonists potentially valuable for men undergoing ADT, both for managing side effects and possibly slowing cancer progression.
Special Considerations and Potential Risks
While the prostate cancer findings are encouraging, it's important to understand the complete picture:
Thyroid Cancer Concerns
Some early research raised concerns about a possible link between GLP-1 agonists and a rare type of thyroid cancer called medullary thyroid carcinoma. However, more recent and comprehensive studies have largely dispelled these concerns. A 2024 Scandinavian study of thousands of patients found no increased thyroid cancer risk with GLP-1 agonist use.
Common Side Effects
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and often improve over time.
Clinical Trials on the Horizon
Researchers are now moving beyond observational studies to conduct dedicated clinical trials:
- Dr. Mohammed Shahait at the University of Sharjah is writing a proposal for a clinical trial specifically assessing GLP-1 agonists in prostate cancer
- Researchers at MD Anderson Cancer Center and other institutions have published a rationale for pre-surgical intervention trials, where men would take GLP-1 agonists before prostate surgery to study the drugs' effects on tumor biology
- Scientists are particularly interested in whether these medications can slow the progression from hormone-sensitive to castration-resistant prostate cancer
A May 2025 review published in the journal Cancers concluded that "GLP-1 receptor agonists seem to be promising, novel, therapeutic agents, especially in advanced and metastatic prostate cancer when standard therapies become insufficient."
Looking Ahead
While current evidence is promising, experts emphasize that more research is needed. Most existing data comes from studies where cancer prevention wasn't the primary goal. Dedicated trials specifically designed to evaluate GLP-1 agonists for prostate cancer prevention and treatment are essential.
Research priorities include:
- Clinical trials specifically designed to assess prostate cancer outcomes
- Long-term studies tracking disease progression in patients taking these medications
- Investigation of which patient populations benefit most
- Optimal dosing and timing strategies
- Potential combination with existing prostate cancer treatments
What Should You Do?
If you're interested in whether a GLP-1 agonist might be appropriate for you, discuss it with your oncologist or primary care physician. Consider these questions for your conversation:
- Do you have metabolic syndrome, diabetes, or obesity that might warrant these medications regardless of potential cancer benefits?
- Are you experiencing weight gain or metabolic changes from ADT?
- What are the potential benefits and risks in your specific situation?
- Are there clinical trials available that might be appropriate for you?
The Bottom Line
The emerging evidence suggesting that GLP-1 agonists may reduce prostate cancer risk is genuinely exciting. These medications appear to work through multiple mechanisms—from directly affecting cancer cells to reducing inflammation and improving metabolic health. The fact that increasing numbers of men with prostate cancer are using these drugs, and that doctors are prescribing them even without traditional indications, reflects growing confidence in their potential value.
However, it's still early days. While observational studies are encouraging, we need dedicated clinical trials to confirm these benefits and understand exactly how to use these medications for maximum effect in prostate cancer prevention and treatment. The good news is that such trials are now being planned.
For men already taking GLP-1 agonists for diabetes or weight management, this research provides reassuring evidence of potential additional benefits. For others, it's a conversation worth having with your healthcare team—especially if you have other risk factors or are experiencing metabolic challenges from prostate cancer treatment.
As always, the IPCSG encourages informed decision-making based on the best available evidence and personalized medical advice from your healthcare providers.
References and Sources
Key Research Studies
- Skriver, C., Friis, S., Knudsen, L.B., Catarig,
A.M., Clark, A.J., Dehlendorff, C., & Mørch, L.S. (2023). Potential
preventive properties of GLP-1 receptor agonists against prostate
cancer: a nationwide cohort study. Diabetologia, 66(11), 2077-2089.
https://link.springer.com/article/10.1007/s00125-023-05972-x - Sharma, N., Khatib, M.N., Balaraman, A.K., et al.
(2024). Effect of GLP-1 receptor agonists on prostate cancer risk
reduction: a systematic review and meta-analysis. International Urology and Nephrology, 57(4), 1039-1049.
https://www.themednet.org/publications/effect-of-glp-1-receptor-agonists-on-prostate-cancer-risk-reduction-a-systematic-review-and-meta-analysis - Knura, M., Garczorz, W., Borek, A., et al. (2025).
May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate
Cancer Aggressiveness and Progression? Cancers, 17(9), 1576.
https://www.mdpi.com/2072-6694/17/9/1576 - Fang, A., Frigo, D.E., Hahn, A., et al. (2025).
GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative
Review and Rationale for Prospective Clinical Trials. Urology. Published online May 8, 2025.
https://www.sciencedirect.com/science/article/abs/pii/S0090429525004261 - Yu, X., & Liu, J. (2024). Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review. Medicine, 103(41), e39956.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11479428/ - Shahait, M., et al. (2024). From Diabetes to
Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role
in Prostate Cancer. Cancers, 16(8), 1588.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11048615/
Recent Conference Presentations and Clinical Data
- Shaver, A.L., Zarrabi, K.K., Nikita, N., Kelly,
W.K., & Lu-Yao, G. (2025). Use of GIP and GLP-1 receptor agonists in
prostate cancer patients. Journal of Clinical Oncology, 43(suppl 17), 5024. [Abstract presented at ASCO 2025 Annual Meeting]
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5024 - Shaver, A. (2025, June 5). GLP-1 agonist use is rising in men with prostate cancer. Urology Times.
https://www.urologytimes.com/view/glp-1-agonist-use-is-rising-in-men-with-prostate-cancer - Metabolic Drugs and Prostate Cancer: Analyzing GLP-1 Agonist Use in Patients – Interview with Amy Shaver, PhD. (2025). UroToday.
https://www.urotoday.com/video-lectures/prostate-cancer/video/4914-metabolic-drugs-and-prostate-cancer-analyzing-glp-1-agonist-use-in-patients-amy-shaver.html
General News and Analysis
- GLP-1 Agonists May One Day Treat Prostate Cancer. (2025, October 26). Managed Healthcare Executive.
https://www.managedhealthcareexecutive.com/view/glp-1-agonists-may-one-day-treat-prostate-cancer - Memorial Sloan Kettering Cancer Center. (2025). Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs.
https://www.mskcc.org/news/cancer-benefits-and-risks-from-ozempic-wegovy-and-other-weight-loss-drugs - Could Ozempic have a protective effect against cancer? (2024, May 15). Drug Discovery World.
https://www.ddw-online.com/could-ozempic-have-a-protective-effect-against-cancer-29741-202405/ - Ozempic reduces risk of 13 types of cancer. (2024, June 10). Drug Discovery World.
https://www.ddw-online.com/ozempic-reduces-risk-of-13-types-of-cancer-30003-202406/ - Ozempic and Wegovy have taken over obesity treatment. Can they help with cancer, too? (2023, May 15). Fierce Biotech.
https://www.fiercebiotech.com/research/drugs-ozempic-boost-cancer-fighting-natural-killer-cells-people-obesity
Related Cancer and Metabolic Research
- Can a novel anti-diabetic, anti-obesity 'wonder drug' be repurposed for cancer? (2024, September 26). Cancer World Magazine.
https://cancerworld.net/can-a-novel-anti-diabetic-drug-repurposed-cancer/ - The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. (2024). Cancer and Metastasis Reviews.
https://link.springer.com/article/10.1007/s10555-024-10192-9
Safety Information
- Semaglutide and Prostate Disorders: What Every Patient Needs to Know. (2025, April 8). BMI Doctors.
https://bmidoctors.com/semaglutide-and-prostate-disorders-what-every-patient-needs-to-know/ - The Connection Between Prostate Health and Semaglutide: A Comprehensive Guide. (2025, April 9). BMI Doctors.
https://bmidoctors.com/the-connection-between-prostate-health-and-semaglutide-a-comprehensive-guide/ - Can Semaglutide Cause Cancer? Know the Potential GLP-1 Risks. (2024, October 1). City of Hope Cancer Center.
https://www.cancercenter.com/community/blog/2024/08/can-semaglutide-cause-cancer
Disclaimer: This article is intended for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider before making decisions about your treatment.
About IPCSG: The Informed Prostate Cancer Support Group (IPCSG) is dedicated to providing evidence-based information to help men and their families make informed decisions about prostate cancer prevention, diagnosis, and treatment.
Could Diabetes Drugs Help Protect Against Prostate Cancer?
New Research Explores Promising Link Between GLP-1 Agonists and Reduced Cancer Risk
IPCSG Newsletter – October 2025
If you've been following health news lately, you've probably heard about GLP-1 agonist medications like Ozempic, Wegovy, and Mounjaro. These drugs have gained widespread attention for helping people manage diabetes and lose weight. But emerging research suggests they may offer an unexpected benefit: protection against prostate cancer.
What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a natural hormone in your body that helps regulate blood sugar and appetite. Originally developed for type 2 diabetes, these drugs have proven remarkably effective for weight management as well.
Common GLP-1 agonists include:
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss)
- Liraglutide (Victoza for diabetes, Saxenda for weight loss)
- Exenatide (Byetta, Bydureon)
- Dulaglutide (Trulicity)
- Tirzepatide (Mounjaro) – a dual GIP/GLP-1 receptor agonist
The Prostate Cancer Connection: What Research Shows
Several recent studies have discovered an intriguing relationship between these medications and prostate cancer risk. The evidence is encouraging:
Large-Scale Population Studies
A major Danish nationwide study published in the journal Diabetologia tracked over 35,000 men for approximately five years. Researchers found that men taking GLP-1 receptor agonists had a 20% lower risk of developing prostate cancer compared to those taking insulin. This protective effect was especially strong in older men and those with cardiovascular disease.
Even more impressive, a comprehensive meta-analysis published in 2024 examined five separate studies and found that GLP-1 receptor agonist use was associated with a 28% reduction in prostate cancer risk compared to placebo or other diabetes medications.
The LEADER Trial Findings
Post-analysis of the LEADER clinical trial, which included over 9,000 patients, revealed that men taking liraglutide had approximately half the risk of developing prostate cancer compared to those receiving placebo.
Recent Real-World Data
Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting examined nearly 2 million prostate cancer patients in the United States. The study found that use of GLP-1 agonists among men with prostate cancer has increased dramatically—from just 1,245 patients in 2015 to 69,808 in 2024. Importantly, doctors are increasingly prescribing these medications to prostate cancer patients even when they don't have traditional indications like diabetes or obesity, suggesting growing confidence in potential benefits.
How Might These Drugs Protect Against Prostate Cancer?
Scientists have identified several mechanisms that may explain the protective effect:
Direct Effects on Cancer Cells
Research has confirmed that GLP-1 receptors are present in prostate cancer tissue. Laboratory studies show that GLP-1 agonists can slow the growth of prostate cancer cells by interfering with signaling pathways that cancer cells use to multiply and survive. Specifically, these drugs appear to block the ERK-MAPK pathway, which is important for cancer cell proliferation.
Reducing Inflammation
Chronic inflammation plays a role in cancer development, and obesity is associated with increased inflammation throughout the body. GLP-1 agonists have been shown to reduce systemic inflammation, which may help create an environment less favorable for cancer growth.
Metabolic Benefits
These medications improve insulin sensitivity and reduce insulin resistance—both factors that have been linked to more aggressive prostate cancer. By addressing metabolic syndrome (a cluster of conditions including high blood pressure, high blood sugar, and abnormal cholesterol levels), GLP-1 agonists may reduce cancer risk indirectly.
Improving Immune Function
A 2023 study published in the journal Obesity found that semaglutide can restore the function of natural killer cells—specialized immune cells that help the body fight cancer. In people with obesity, these cells often become less effective, but GLP-1 agonists appear to reverse this impairment.
Increasing Use Among Prostate Cancer Patients
As awareness of these potential benefits grows, more men with prostate cancer are being prescribed GLP-1 agonists. The 2025 ASCO data shows particularly interesting trends:
- About 6% of prostate cancer patients now use these medications—matching the rate in the general population
- In 2024, 81% of prostate cancer patients on GLP-1 agonists had type 2 diabetes (down from 87% in 2015)
- An increasing number of patients are receiving these drugs without traditional diabetes or obesity indications, suggesting doctors may be prescribing them for potential cancer-related benefits
- Patients with lower social vulnerability and those who are obese are more likely to receive these medications
What This Means for Men with Prostate Cancer
The relationship between androgen deprivation therapy (ADT)—a common prostate cancer treatment—and metabolic health is particularly relevant. ADT often leads to weight gain and increased cardiovascular risks, creating a perfect storm for metabolic syndrome. This makes GLP-1 agonists potentially valuable for men undergoing ADT, both for managing side effects and possibly slowing cancer progression.
Special Considerations and Potential Risks
While the prostate cancer findings are encouraging, it's important to understand the complete picture:
Thyroid Cancer Concerns
Some early research raised concerns about a possible link between GLP-1 agonists and a rare type of thyroid cancer called medullary thyroid carcinoma. However, more recent and comprehensive studies have largely dispelled these concerns. A 2024 Scandinavian study of thousands of patients found no increased thyroid cancer risk with GLP-1 agonist use.
Common Side Effects
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and often improve over time.
Clinical Trials on the Horizon
Researchers are now moving beyond observational studies to conduct dedicated clinical trials:
- Dr. Mohammed Shahait at the University of Sharjah is writing a proposal for a clinical trial specifically assessing GLP-1 agonists in prostate cancer
- Researchers at MD Anderson Cancer Center and other institutions have published a rationale for pre-surgical intervention trials, where men would take GLP-1 agonists before prostate surgery to study the drugs' effects on tumor biology
- Scientists are particularly interested in whether these medications can slow the progression from hormone-sensitive to castration-resistant prostate cancer
A May 2025 review published in the journal Cancers concluded that "GLP-1 receptor agonists seem to be promising, novel, therapeutic agents, especially in advanced and metastatic prostate cancer when standard therapies become insufficient."
Looking Ahead
While current evidence is promising, experts emphasize that more research is needed. Most existing data comes from studies where cancer prevention wasn't the primary goal. Dedicated trials specifically designed to evaluate GLP-1 agonists for prostate cancer prevention and treatment are essential.
Research priorities include:
- Clinical trials specifically designed to assess prostate cancer outcomes
- Long-term studies tracking disease progression in patients taking these medications
- Investigation of which patient populations benefit most
- Optimal dosing and timing strategies
- Potential combination with existing prostate cancer treatments
What Should You Do?
If you're interested in whether a GLP-1 agonist might be appropriate for you, discuss it with your oncologist or primary care physician. Consider these questions for your conversation:
- Do you have metabolic syndrome, diabetes, or obesity that might warrant these medications regardless of potential cancer benefits?
- Are you experiencing weight gain or metabolic changes from ADT?
- What are the potential benefits and risks in your specific situation?
- Are there clinical trials available that might be appropriate for you?
The Bottom Line
The emerging evidence suggesting that GLP-1 agonists may reduce prostate cancer risk is genuinely exciting. These medications appear to work through multiple mechanisms—from directly affecting cancer cells to reducing inflammation and improving metabolic health. The fact that increasing numbers of men with prostate cancer are using these drugs, and that doctors are prescribing them even without traditional indications, reflects growing confidence in their potential value.
However, it's still early days. While observational studies are encouraging, we need dedicated clinical trials to confirm these benefits and understand exactly how to use these medications for maximum effect in prostate cancer prevention and treatment. The good news is that such trials are now being planned.
For men already taking GLP-1 agonists for diabetes or weight management, this research provides reassuring evidence of potential additional benefits. For others, it's a conversation worth having with your healthcare team—especially if you have other risk factors or are experiencing metabolic challenges from prostate cancer treatment.
As always, the IPCSG encourages informed decision-making based on the best available evidence and personalized medical advice from your healthcare providers.
References and Sources
Key Research Studies
- Skriver, C., Friis, S., Knudsen, L.B., Catarig, A.M., Clark, A.J., Dehlendorff, C., & Mørch, L.S. (2023). Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia, 66(11), 2077-2089.
https://link.springer.com/article/10.1007/s00125-023-05972-x - Sharma, N., Khatib, M.N., Balaraman, A.K., et al. (2024). Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis. International Urology and Nephrology, 57(4), 1039-1049.
https://www.themednet.org/publications/effect-of-glp-1-receptor-agonists-on-prostate-cancer-risk-reduction-a-systematic-review-and-meta-analysis - Knura, M., Garczorz, W., Borek, A., et al. (2025). May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression? Cancers, 17(9), 1576.
https://www.mdpi.com/2072-6694/17/9/1576 - Fang, A., Frigo, D.E., Hahn, A., et al. (2025). GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials. Urology. Published online May 8, 2025.
https://www.sciencedirect.com/science/article/abs/pii/S0090429525004261 - Yu, X., & Liu, J. (2024). Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review. Medicine, 103(41), e39956.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11479428/ - Shahait, M., et al. (2024). From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer. Cancers, 16(8), 1588.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11048615/
Recent Conference Presentations and Clinical Data
- Shaver, A.L., Zarrabi, K.K., Nikita, N., Kelly, W.K., & Lu-Yao, G. (2025). Use of GIP and GLP-1 receptor agonists in prostate cancer patients. Journal of Clinical Oncology, 43(suppl 17), 5024. [Abstract presented at ASCO 2025 Annual Meeting]
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5024 - Shaver, A. (2025, June 5). GLP-1 agonist use is rising in men with prostate cancer. Urology Times.
https://www.urologytimes.com/view/glp-1-agonist-use-is-rising-in-men-with-prostate-cancer - Metabolic Drugs and Prostate Cancer: Analyzing GLP-1 Agonist Use in Patients – Interview with Amy Shaver, PhD. (2025). UroToday.
https://www.urotoday.com/video-lectures/prostate-cancer/video/4914-metabolic-drugs-and-prostate-cancer-analyzing-glp-1-agonist-use-in-patients-amy-shaver.html
General News and Analysis
- GLP-1 Agonists May One Day Treat Prostate Cancer. (2025, October 26). Managed Healthcare Executive.
https://www.managedhealthcareexecutive.com/view/glp-1-agonists-may-one-day-treat-prostate-cancer - Memorial Sloan Kettering Cancer Center. (2025). Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs.
https://www.mskcc.org/news/cancer-benefits-and-risks-from-ozempic-wegovy-and-other-weight-loss-drugs - Could Ozempic have a protective effect against cancer? (2024, May 15). Drug Discovery World.
https://www.ddw-online.com/could-ozempic-have-a-protective-effect-against-cancer-29741-202405/ - Ozempic reduces risk of 13 types of cancer. (2024, June 10). Drug Discovery World.
https://www.ddw-online.com/ozempic-reduces-risk-of-13-types-of-cancer-30003-202406/ - Ozempic and Wegovy have taken over obesity treatment. Can they help with cancer, too? (2023, May 15). Fierce Biotech.
https://www.fiercebiotech.com/research/drugs-ozempic-boost-cancer-fighting-natural-killer-cells-people-obesity
Related Cancer and Metabolic Research
- Can a novel anti-diabetic, anti-obesity 'wonder drug' be repurposed for cancer? (2024, September 26). Cancer World Magazine.
https://cancerworld.net/can-a-novel-anti-diabetic-drug-repurposed-cancer/ - The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. (2024). Cancer and Metastasis Reviews.
https://link.springer.com/article/10.1007/s10555-024-10192-9
Safety Information
- Semaglutide and Prostate Disorders: What Every Patient Needs to Know. (2025, April 8). BMI Doctors.
https://bmidoctors.com/semaglutide-and-prostate-disorders-what-every-patient-needs-to-know/ - The Connection Between Prostate Health and Semaglutide: A Comprehensive Guide. (2025, April 9). BMI Doctors.
https://bmidoctors.com/the-connection-between-prostate-health-and-semaglutide-a-comprehensive-guide/ - Can Semaglutide Cause Cancer? Know the Potential GLP-1 Risks. (2024, October 1). City of Hope Cancer Center.
https://www.cancercenter.com/community/blog/2024/08/can-semaglutide-cause-cancer
Disclaimer: This article is intended for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider before making decisions about your treatment.
About IPCSG: The Informed Prostate Cancer Support Group (IPCSG) is dedicated to providing evidence-based information to help men and their families make informed decisions about prostate cancer prevention, diagnosis, and treatment.
Comments
Post a Comment